← Back to patent-cliff list
Ensifentrine
Tier C — Watch / tradeEnsifentrine
Vernalis Plc
Originator
2024
First approval
-
Expiry (public)
$0.18B ▲
Peak sales
Small molecule
Type
Targets：PDE3, PDE4
Brand：Ohtuvayre
Indications (approved)：Chronic obstructive pulmonary disease
Regional status
US
Approved
2024-06-26
EU
Phase III
2020-09-22
China
Phase III
2023-03-10
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ensifentrine?
Approved indications include: Chronic obstructive pulmonary disease.
When does the Ensifentrine patent expire?
No public expiry year is available for Ensifentrine yet; this page updates once verified.
How do I get a quote for Ensifentrine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27